The Mark Lazarev Lab performs clinical research on Inflammatory Bowel Disease.

The Tsion Abdi Lab performs clinical research on Scleroderma Bowel Disease and Inflammatory Bowel Disease.

The Joanna Peloquin Lab focuses on inflammatory bowel disease (IBD). We're working on individualized care for IBD patients through functional genomic studies, specifically those related to diet, host and microbiota interactions.

The Melia lab performs basic, translational, and clinical research on inflammatory bowel disease. Specifically, Dr Melia's basic science and translational research program is concentrated on novel roles of manganese (Mn) homeostasis in Crohn's disease and the interaction with aberrant N-glycosylation with current support from NIDDK and NICHD, including support as a co-investigator in the Center for Metals in Nutrition and Development.

Investigators in the IBD and Autoimmune Liver Diseases Laboratory conduct basic and translational research in inflammatory bowel disease (IBD) and autoimmune liver diseases. One area of focus is discovering and developing biomarkers for diagnosing and prognosticating IBD and other autoimmune liver diseases (AILDs). We also are exploring the molecular pathogenesis of—and developing novel therapies for—IBD. In addition, we are working to understand the molecular reason why many IBD patients fail to respond to mainstay drug therapies—and to develop diagnostic assays that can predict non-responders before starting them on those therapies. These biomarker studies have led to our application for four U.S. and international patents.

The Zhu lab is focused on characterizing the activities of large collection of proteins, building signaling networks for better understanding the mechanisms of biological processes, and identifying biomarkers in human diseases and cancers. More specifically, our group is interested in analyzing protein posttranslational modifications, and identifying important components involved in transcription networks and host-pathogen interactions on the proteomics level, and biomarkers in human IBD diseases.

Dr. Florin Selaru is the director of the Johns Hopkins Inflammatory Bowel disease Center and the research interests in the Selaru Lab comprise the molecular changes associated with the transition from inflammatory states in the GI tract (colon, stomach, biliary tree) to frank cancers. In addition, our current research funded by the AGA, FAMRI and the Broad Foundation works to further the understanding of cancer development and progression in the gastrointestinal tract. Additional areas of investigation include collaboration with biomedical engineers to develop novel compounds for the treatment of IBD associated fistulizing disease, as well as new techniques for administering medications directly to inflamed GI tissues.